Recent News
Through Partnership with The Chase Group, Aeglea BioTherapeutics Continues Building Rare Disease Clinical Development Leadership Team
The Chase Group is honored to continue our partnership with Aeglea BioTherapeutics as we work to build their Rare Disease Clinical Development Leadership team. As… Continue Reading →Data Science Leadership Team Set to Expand with The Chase Group/Genmab Partnership
The Chase Group is proud to be partnering with Genmab, a publicly traded, international, biotechnology company with the goal of transforming oncology research by discovering… Continue Reading →
Eli Lilly Partnership Continues in Medical Affairs Oncology
Eli Lilly continues to partner with The Chase Group to build the Medical Affairs Oncology team for their Cyramza® portfolio. The Chase Group is currently… Continue Reading →Genmab Selects The Chase Group to Build Data Science Team
Genmab A/S specializes in the creation and development of antibody therapeutics for the treatment of cancer. When highly specialized talent is needed, Genmab relies on… Continue Reading →Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate… Continue Reading →Oncology Teams Set to Grow with Eli Lilly and The Chase Group Partnership
Lilly Oncology is known for its exciting pipeline across multiple tumor types and dedication to addressing the unmet needs of people living with cancer. Their… Continue Reading →The Chase Group Secures the Vice President, US and Global Medical Affairs for Eli Lilly
The Chase Group is pleased to announce the successful completion of the Vice President, US and Global Medical Affairs at Eli Lilly. The new Vice… Continue Reading →Aeglea BioTherapeutics (NASDAQ: AGLE) Partners with The Chase Group to Build Clinical Development Team for Rapidly Expanding Genetic Rare Disease Portfolio
As a leader in engineering human enzymes to address significant unmet medical needs in rare genetic diseases and cancer, Aeglea BioTherapeutics is committed to using… Continue Reading →